APA Alıntı

Pugliese, D., Felice, C., Landi, R., Papa, A., Guidi, L., & Armuzzi, A. (2016). Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis. Drug Healthc Patient Saf.

Chicago Stili Alıntı

Pugliese, Daniela, Carla Felice, Rosario Landi, Alfredo Papa, Luisa Guidi, ve Alessandro Armuzzi. "Benefit–risk Assessment of Golimumab in the Treatment of Refractory Ulcerative Colitis." Drug Healthc Patient Saf 2016.

MLA Alıntı

Pugliese, Daniela, et al. "Benefit–risk Assessment of Golimumab in the Treatment of Refractory Ulcerative Colitis." Drug Healthc Patient Saf 2016.